Genetics in MedicineGenetic & Genomic MedicinePeer-reviewed journal article
One in seven pathogenic variants can be challenging to detect by NGS: An analysis of 450,000 patients with implications for clinical sensitivity and genetic test implementation
Stephen E. LincolniD, Tina M. HambuchiD, Justin M. ZookiD, Sara L. BristowiD, Kathryn E. HatchelliD, Rebecca TrutyiD, Michael I. Kennemer, Brian H. ShirtsiD, ANDREW P. FELLOWESiD, Shimul ChowdhuryiD, Eric W. KleeiD, Shazia Mahamdallie, Megan H. ClevelandiD, Peter M. ValloneiD, Yan DingiD, Sheila Seal, Wasanthi DeSilva, Farol L. Tomson, Catherine Huang, Russell K. GarlickiD, Nazneen RahmaniD, Marc SalitiD, Stephen Francis KingsmoreiD, Matthew J. FerberiD, Swaroop AradhyaiD, Robert Luke NussbaumiD
Abstract
PurposeTo evaluate the impact of technically challenging variants on the implementation, validation, and diagnostic yield of commonly used clinical genetic tests. Such variants include large indels, small CNVs, complex alterations, and variants in low-complexity or segmentally duplicated regions. MethodsAn interlaboratory pilot study used novel synthetic specimens to assess detection of challenging variant types by various NGS-based workflows. One well-performing workflow was further validated and used in clinician-ordered testing of more than 450,000 patients. ResultsIn the interlaboratory study, only two of 13 challenging variants were detected by all 10 workflows, and just three workflows detected all 13. Limitations were also observed among 11 less-challenging indels. In clinical testing, 21.6% of patients carried one or more pathogenic variants, of which 13.8% (17,561) were classified as technically challenging. These variants were of diverse types, affecting 556 of 1,217 genes across hereditary cancer, cardiovascular, neurological, pediatric, reproductive carrier screening, and other indicated tests. ConclusionThe analytic and clinical sensitivity of NGS workflows can vary considerably, particularly for prevalent, technically challenging variants. This can have important implications for the design and validation of tests (by laboratories) and the selection of tests (by clinicians) for a wide range of clinical indications.
- organism: human
- assay: whole-exome sequencing
- research focus: variant calling
- approach: experimental assay
- Citations
- 91
- FWCI
- 8.33
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- An interlaboratory study of complex variant detection
Stephen E. Lincoln, Justin M. Zook, … Brian H. Shirts·bioRxiv·Nov 23, 2017
- A Rigorous Interlaboratory Examination of the Need to Confirm NGS-Detected Variants by an Orthogonal Method in Clinical Genetic Testing
Stephen E. Lincoln, Rebecca Truty, … Matthew S. Lebo·Journal of Molecular DiagnosticsPeer-reviewed·Jan 2, 2019
- NGS-based assay for frequent newborn inherited diseases: from development to implementation
T. Simakova, A. Bragin, … A. Pavlov·bioRxiv·Apr 26, 2016
- Genome sequencing as a generic diagnostic strategy for rare disease
Gaby Schobers, Ronny C. Derks, … Lisenka E.L.M. Vissers·medRxiv·Sep 28, 2023
- Evaluation of false positive and false negative errors in targeted next generation sequencing
Youngbeen Moon, Young-Ho Kim, … Kyeong‐Man Hong·Genome biologyPeer-reviewed·Dec 1, 2025
- Sanger validation of WGS variants - when to?
Arina Kopernik, Г.Ю. Зобкова, … Pavel Volchkov·bioRxiv·Apr 19, 2024